Meseclazone (W2395;NSC297623) exhibits inhibitory potency of secondary phase ADP aggregation. Meseclazone possesses anti-inflammatory, analgesic and antipyretic activity.

Product information

CAS Number: 29053-27-8

Molecular Weight: 239.66

Formula: C11H10ClNO3

Chemical Name: 11-chloro-5-methyl-2,6-dioxa-7-azatricyclo[7.4.0.0³,⁷]trideca-1(13),9,11-trien-8-one

Smiles: CC1CC2OC3=CC=C(Cl)C=C3C(=O)N2O1

InChiKey: OJGJQQNLRVNIKE-UHFFFAOYSA-N

InChi: InChI=1S/C11H10ClNO3/c1-6-4-10-13(16-6)11(14)8-5-7(12)2-3-9(8)15-10/h2-3,5-6,10H,4H2,1H3

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vivo:

Meseclazone inhibits collagen-induced aggregation 1 and 4 hr after oral administration. Intravenous administration of Meseclazone and other nonsteroidal anti-inflammatory drugs caused a dose-dependent inhibition of bronchoconstriction resulting in the following order of descending potency: isoproterenol congruent to indomethacin greater than fenoprofen greater than tolmetin greater than aspirin greater than naproxen congruent to ibuprofen greater than phenylbutazone greater than diflunisal greater than Meseclazone greater than 5-CSA.

Products are for research use only. Not for human use.